Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 2/20 | 0.46 |
| ▸ | SLC5A2 | P31639 | 4/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | GMNN | O75496 | 2/20 | 0.42 |
| ▸ | BLM | P54132 | 2/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | STAT6 | P42226 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17262432 | 1.00 | PYGL (0.46) | PYGLSLC5A2HIF1ALMNASMN1; SMN2 | |
| SCHEMBL28707545 | 1.00 | PYGL (0.46) | PYGLSLC5A2HIF1ALMNASMN1; SMN2 | |
| Triphosphate SCHEMBL29244948 | 0.88 | P2RY2 (0.42) | PYGLSLC5A2HIF1A | |
| SCHEMBL11180532 | 0.75 | PYGL (0.58) | PYGLSLC5A2HIF1A | |
| SCHEMBL30423786 | 0.73 | PYGL (0.43) | PYGLSLC5A2HIF1ALMNASMN1; SMN2 | |
| SCHEMBL6760097 | 0.70 | HIF1A (0.52) | HIF1ALMNASMN1; SMN2GMNNBLM | |
| SCHEMBL7210923 | 0.70 | LMNA (0.46) | PYGLSLC5A2HIF1ALMNAMTOR | |
| SCHEMBL20581714 | 0.69 | LMNA (0.50) | PYGLHIF1ALMNASMN1; SMN2GMNN | |
| Phosphoric Acid SCHEMBL30423228 | 0.68 | PNP (0.40) | PYGLSLC5A2HIF1ALMNASMN1; SMN2 | |
| SCHEMBL10663518 | 0.68 | HIF1A (0.46) | PYGLHIF1ALMNASMN1; SMN2GMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697812-B2 | Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2023-07-11 | — | — | US | claimed |
| US-11359198-B2 | Extended dicer substrate agents and methods for the specific inhibition of gene expression | DICERNA PHARMACEUTICALS, INC. (US) | 2022-06-14 | — | — | US | claimed |
| EP-3865576-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | Dicerna Pharmaceuticals, Inc. (US) | 2021-08-18 | — | — | EP | claimed |
| US-10870849-B2 | Extended dicer substrate agents and methods for the specific inhibition of gene expression | DICERNA PHARMACEUTICALS, INC. (US) | 2020-12-22 | — | — | US | claimed |
| US-10837013-B2 | Extended dicer substrate agents and methods for the specific inhibition of gene expression | DICERNA PHARMACEUTICALS, INC. (US) | 2020-11-17 | — | — | US | claimed |
| US-20200031862-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | DICERNA PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | claimed |
| EP-3234132-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | Dicerna Pharmaceuticals, Inc. (US) | 2017-10-25 | — | — | EP | claimed |
| WO-2016100401-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | DICERNA PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | claimed |
| US-20150038554-A1 | Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression | NOVO NORDISK A/S (DK) | 2015-02-05 | — | — | US | claimed |
| US-20150038555-A1 | Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression | NOVO NORDISK A/S (DK) | 2015-02-05 | — | — | US | claimed |
| US-20130041010-A1 | COMPOSITIONS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DSRNA CONTAINING MODIFIED NUCLEOTIDES | DICERNA PHARMACEUTICALS, INC. (US) | 2013-02-14 | — | — | US | claimed |
| US-20110288147-A1 | Compositions and methods for the specific inhibition of gene expression by DSRNA containing a tetraloop | DICERNA PHARMACEUTICALS, INC. | 2011-11-24 | — | — | US | claimed |
| US-20100331389-A1 | Compositions and methods for the specific inhibition of gene expression by dsRNA containing modified nucleotides | DICERNA PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | claimed |
| US-20240229037-A1 | SIRNA TARGETING 17Beta-HYDROXYSTEROID DEHYDROGENASE TYPE 13 AND SIRNA CONJUGATE | TUOJIE BIOTECH (SHANGHAI) CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| EP-4328310-A1 | SIRNA TARGETING 17B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 AND SIRNA CONJUGATE | Tuojie Biotech (Shanghai) Co., Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| US-11912996-B2 | Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20100184841-A1 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | DICERNA PHARMACEUTICALS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2010080129-A2 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | DICERNA PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| US-20100173974-A1 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | DICERNA PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100173973-A1 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | DICERNA PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031862-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | ADAR, NCL, SSU72 | PYGL 4386/4885SLC5A2 4392/4885HIF1A 4250/4885 |
| US-20100184841-A1 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | RNASE1, AGO2, DCLRE1B | PYGL 4656/4885SLC5A2 4835/4885HIF1A 3171/4885 |
| US-20100173973-A1 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | RNASE1, AGO2, DCLRE1B | PYGL 4656/4885SLC5A2 4835/4885HIF1A 3171/4885 |
| US-11697812-B2 | Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA | TTR, RNASE1, SARNP | PYGL 2303/4885SLC5A2 4284/4885HIF1A 3955/4885 |
| US-20240229037-A1 | SIRNA TARGETING 17Beta-HYDROXYSTEROID DEHYDROGENASE TYPE 13 AND SIRNA CONJUGATE | HSD17B13, HSD17B1, HSD17B3 | PYGL 28/4885SLC5A2 4229/4885HIF1A 1370/4885 |
| US-20100173974-A1 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | RNASE1, AGO2, DCLRE1B | PYGL 4656/4885SLC5A2 4835/4885HIF1A 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.